NOVO NORDISK PHARMACEUTICALS A/S: Financial statements 2014
CVR: 24257924
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
NOVO NORDISK PHARMACEUTICALS A/S (CVR 24257924) has filed annual accounts for 2014. In 2014, the company reported a net result of DKK 3,150,000. Equity in the 2014 report amounted to DKK 12,543,000. The solvency ratio was 99.7%.
- Profit/Loss
- DKK 3,150,000
- Equity
- DKK 12,543,000
- Total Assets
- DKK 12,579,000
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2013.
As of July 1, 2014, Karsten Munk Knudsen is registered as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of July 1, 2014, Lars Green has stepped down as adm. dir. of NOVO NORDISK PHARMACEUTICALS A/S.
About NOVO NORDISK PHARMACEUTICALS A/S
NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.
